We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
126
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.21M 0.04%
21,500
+7,000
+48% +$545K
QURE icon
127
uniQure
QURE
$2.71B
$2.16M 0.04%
27,600
-10,700
-28% -$682K
GWPH
128
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.13M 0.04%
12,353
– –
ASND icon
129
Ascendis Pharma A/S
ASND
$16.6B
$2.1M 0.04%
18,200
– –
CTLT
130
DELISTED
CATALENT, INC.
CTLT
$2.03M 0.03%
+37,500
New +$1.72M
LABD icon
131
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$63.1M
$2.02M 0.03%
560
+185
+49% +$779K
FOLD
132
DELISTED
Amicus Therapeutics
FOLD
$1.87M 0.03%
150,000
– –
PFE icon
133
Pfizer
PFE
$143B
$1.73M 0.03%
42,160
– –
RGNX icon
134
Regenxbio
RGNX
$656M
$1.7M 0.03%
33,100
– –
MDCO
135
DELISTED
Medicines Co
MDCO
$1.59M 0.03%
43,500
+14,500
+50% +$473K
BPMC
136
DELISTED
Blueprint Medicines
BPMC
$1.46M 0.03%
+15,500
New +$1.28M
RARE icon
137
Ultragenyx Pharmaceutical
RARE
$2.66B
$1.45M 0.02%
22,800
-7,000
-23% -$446K
WCG
138
DELISTED
Wellcare Health Plans, Inc.
WCG
$1.38M 0.02%
4,851
-102,568
-95% -$28.3M
FATE icon
139
Fate Therapeutics
FATE
$294M
$1.2M 0.02%
+59,000
New +$1.06M
LH icon
140
Labcorp
LH
$23.9B
$1M 0.02%
6,731
-73
-1% -$10.2K
ANAB icon
141
AnaptysBio
ANAB
$1.63B
$959K 0.02%
+17,000
New +$1.22M
MCK icon
142
McKesson
MCK
$96.5B
$826K 0.01%
6,149
-37
-0.6% -$4.61K
VKTX icon
143
Viking Therapeutics
VKTX
$4.11B
$797K 0.01%
+96,000
New +$820K
AUTL
144
Autolus Therapeutics
AUTL
$405M
$547K 0.01%
+34,000
New +$760K
MELI icon
145
Mercado Libre
MELI
$91.2B
$511K 0.01%
+835
New +$465K
AFMD
146
DELISTED
Affimed
AFMD
$481K 0.01%
16,750
– –
BIS icon
147
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.27M
$426K 0.01%
+3,125
New +$457K
MSCI icon
148
MSCI
MSCI
$40.2B
$426K 0.01%
+1,786
New +$400K
MKTX icon
149
MarketAxess Holdings
MKTX
$4.06B
$425K 0.01%
+1,322
New +$382K
EL icon
150
Estee Lauder
EL
$28.9B
$412K 0.01%
+2,248
New +$384K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.